A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation
Lynn R. Webster(Adherent Technologies (United States)), Jaakko Lappalainen(Wilmington University), Ulysses Diva(Korean Red Cross), Raj Tummala(Hofstra University)
Cited by 17
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|The Lancet Rheumatology|2019|478
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331